On May 21, 2026, Eli Lilly released the TRIUMPH-1 results, and the number that should have stopped every lifter mid-scroll was not the headline 28.3%. It was the 104-week extension data showing weight loss reaching 30.3% in participants with BMI over 35 — with no plateau. Two full years of progressive fat loss, averaging roughly 85 pounds, without the weight-loss curve flattening. That has never happened with a pharmacologic intervention. It is bariatric-surgery territory achieved with a once-weekly injection.
⚡ Key Takeaway
Retatrutide produced 28.3% average weight loss at 80 weeks (TRIUMPH-1, 2,339 patients) with 45.3% of 12mg patients losing 30% or more. The 104-week extension showed no plateau at 30.3% — a first for any drug. It is not FDA-approved and cannot be prescribed. NDA filing is expected Q4 2026.
The Numbers That Matter for Physique
TRIUMPH-1 enrolled 2,339 adults with obesity or overweight plus at least one weight-related comorbidity, without diabetes. The 12mg dose — the dose that will likely go to market — produced 28.3% average weight loss at 80 weeks. That is approximately 70 pounds for the average participant. But the distribution is what makes this different from semaglutide: 45.3% of participants on the 12mg dose lost 30% or more of their body weight. Nearly half the group hit a threshold that previously required surgical intervention.
For context, semaglutide (Wegovy) produces roughly 15% weight loss at 68 weeks. Tirzepatide (Zepbound) produces roughly 20-22%. Retatrutide at 28.3% represents a 30-40% improvement over the current best-in-class, and the no-plateau finding at 104 weeks suggests the ceiling has not been reached.
Triple Agonism: Why Retatrutide Hits Different
Retatrutide is a first-in-class triple hormone receptor agonist, simultaneously activating GLP-1, GIP, and glucagon receptors. This matters for physique beyond just the weight number. GLP-1 activation slows gastric emptying and suppresses appetite — the mechanism shared by semaglutide. GIP activation enhances insulin secretion and works synergistically with GLP-1 — the mechanism that let tirzepatide outperform semaglutide. Glucagon activation is the new variable, and it is the one that changes the recomp calculation.
Glucagon promotes hepatic fat oxidation and energy expenditure. In simple terms: it tells your liver to burn fat for energy and increases your basal metabolic rate. This is mechanistically distinct from the appetite-suppression pathway that GLP-1 and GIP provide. You are eating less (GLP-1/GIP) while simultaneously burning more at rest (glucagon). The combination is why the weight loss numbers exceed what dual agonists can achieve.
The Recomp Question Nobody Is Asking Honestly
Here is the part the weight-loss headlines skip: how much of that 28.3% is fat versus lean mass? Across the GLP-1 class, roughly 20-40% of weight lost is lean tissue, including muscle. At 70 pounds of total loss, even a conservative 25% lean-mass fraction means losing 17-18 pounds of muscle. For anyone who has spent years building muscle, that is not a rounding error.
The TRIUMPH-1 data has not yet reported detailed body composition breakdowns with DXA or similar precision imaging. That data will come with the full publication, but it is the critical missing variable for anyone evaluating retatrutide through a physique lens rather than a pure weight-loss lens.
The glucagon component may partially offset this problem. Glucagon’s metabolic action favors fat oxidation specifically, which could theoretically preserve more lean mass than a pure appetite-suppression approach. But “could theoretically” is not “has been demonstrated,” and until the composition data is published, the muscle-loss question remains open.
TRIUMPH-4 and the Joint Pain Finding
TRIUMPH-4, which reported in December 2025 with 28.7% weight loss in obesity plus osteoarthritis patients, added another data point that matters for lifters: significant reduction in knee osteoarthritis pain. Obesity-related joint pain is one of the primary reasons heavy men modify or abandon training programs. If retatrutide can reduce that pain through weight loss while preserving enough function to maintain training, the downstream effects on long-term body composition could compound.
The TRANSCEND-T2D-1 data, published in The Lancet in June 2026, showed 16.8% weight loss at 40 weeks in type 2 diabetes patients — notable because metabolic conditions typically reduce GLP-1 drug efficacy. The diabetes indication matters commercially because Medicare coverage for diabetes is broader than for obesity alone.
The Access Reality in 2026
Retatrutide is not FDA-approved. It is not available by prescription. The NDA filing is expected Q4 2026, with FDA review projected through late 2027 and potential commercial launch in Q1-Q2 2028. That is a minimum 18-month timeline before legitimate access opens up.
In the meantime, a CBS News investigation in June 2026 documented dozens of clinics across the country openly advertising retatrutide prescriptions, staffed by licensed physicians operating outside the bounds of current law. The research-grade market is similarly active. If you are considering retatrutide from any source, the standard applies with extra emphasis: verify the Certificate of Analysis, ensure independent third-party testing, and understand that you are using an investigational compound with a Phase 3 safety profile that is promising but not yet reviewed by the FDA.